Compare Newmont Corporation (NEM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs TG Therapeutics Inc — how do they compare? Newmont Corporation trades at $92.41 (market cap $95.23B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Newmont Corporation is far larger — about 11.5× TG Therapeutics Inc's market cap, and Newmont Corporation pays a 1.17% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NEM | TGTX | |
|---|---|---|
Market Cap | $95.23B | $8.26B |
Sector | Basic Materials | Health |
52-Week High | $131.95 | $59.06 |
52-Week Low | $59.86 | $26.39 |
Enterprise Value | $91.98B | $8.50B |
Dividend Yield | 1.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
